Regulators clear Cytocom to launch Phase II study of COVID treatment

FORT COLLINS — The U.S. Food and Drug Administration has granted Cytocom Inc. permission to begin a Phase II trial of a drug candidate it believes could treat patients with symptomatic COVID-19.

Study Information provided to regulators shows that Cytocom intends to recruit 75 participants and anticipates starting the trials next month at a hospital in California. The Fort Collins company anticipates completing the study next April.

The drug being studied is naltrexone hydrochloride, a similar compound to Narcan that is used to treat alcohol and drug addiction at doses between 50 to 100 milligrams. Cytocom believes that naltrexone issued at…